BioSpace News Archive

BioMidwest

Eli Lilly and AbCellera Dose First Patients with COVID-19 Antibody in Phase I Study

The two companies were able to get their antibody candidate into the clinic within two months of announcing their collaboration in response to the global pandemic.

June 1, 2020
·
2 min read
·
Alex Keown
FDA

Genentech’s Tecentriq-Avastin Combo Approved for HCC, an Improvement on Standard of Care

Tecentriq is an anti-PD-L1 checkpoint inhibitor. Avastin binds to the VEGF protein, which plays a significant role in the development and maintenance of blood vessels by cancer cells.

June 1, 2020
·
3 min read
·
Mark Terry
Biotech Bay

ASCO Highlights: Takeda, Genentech, Johnson & Johnson and More

The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.

June 1, 2020
·
6 min read
·
Mark Terry
FDA

FDA Approves New Treatment Oriahnn for Heavy Menstrual Bleeding Associated with Uterine Fibroids

AbbVie won first-of-its-kind approval for a non-surgical treatment, Oriahnn, aimed at treating heavy menstrual bleeding due to uterine fibroids, a common non-cancerous tumor, in pre-menopausal women.

June 1, 2020
·
2 min read
·
Alex Keown
Drug Development

Myovant’s Prostate Cancer Drug Relugolix Demonstrates Strong Data in Phase III

The company presented the data at the American Society of Clinical Oncology Virtual Scientific Program and also published data simultaneously in the New England Journal of Medicine.

June 1, 2020
·
3 min read
·
Mark Terry
Business

Regeneron and Intellia Expand Their Hunt for Hemophilia A and B Treatments

Regeneron Pharmaceuticals and Intellia Therapeutics announced on Monday that they will be expanding an existing collaboration.

June 1, 2020
·
3 min read
·
Krystle Vermes
Drug Development

Late-Stage Trial Results Show Remdesivir Improves Outcomes in Moderate COVID-19 Patients

In the 5-day remdesivir group, patients were 65% more likely to see clinical improvement at 11 days compared to those treated with standard-of-care only.

June 1, 2020
·
3 min read
·
Alex Keown
Business

Why Cell and Gene Therapies Need a Paradigm Shift to Enable Commercial Scale-up

Cell and gene therapies must scale up on an industrial level if they are to deliver their full potential to patients worldwide, according to speakers at the International Society of Cell Therapy meeting, ISCT Paris 2020 Virtual, May 29.

June 1, 2020
·
5 min read
·
Gail Dutton
Drug Development

Pfizer Shares Dipped Following Release of Phase III Palbociclib Study Data

Pfizer shared results from the trial on Friday, and the data determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival in patients with breast cancer.

June 1, 2020
·
2 min read
·
Krystle Vermes
Business

AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors

AbbVie, a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells.

June 1, 2020
·
3 min read